Cergentis TLA Technology

Cergentis has launched its Target Locus Amplification (TLA) technology for sequencing complete cancer genes. TLA relies on DNA crosslinking and has advantages for analyzing DNA from FFPE tumor samples, according to the company, which is based in Utrecht, the Netherlands. It analyzes both single nucleotide variants and structural variants.